1. Home
  2. EARN vs IPHA Comparison

EARN vs IPHA Comparison

Compare EARN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

HOLD

Current Price

$5.28

Market Cap

189.7M

Sector

Real Estate

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.70

Market Cap

174.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EARN
IPHA
Founded
2012
1999
Country
United States
France
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
189.7M
174.2M
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
EARN
IPHA
Price
$5.28
$1.70
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$5.88
$5.00
AVG Volume (30 Days)
316.4K
26.6K
Earning Date
02-20-2026
09-17-2025
Dividend Yield
18.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$35,893,000.00
$14,839,695.00
Revenue This Year
$8.43
$22.29
Revenue Next Year
$17.27
$43.90
P/E Ratio
N/A
N/A
Revenue Growth
43.30
N/A
52 Week Low
$4.33
$1.60
52 Week High
$6.86
$2.63

Technical Indicators

Market Signals
Indicator
EARN
IPHA
Relative Strength Index (RSI) 51.85 36.12
Support Level $5.15 $1.64
Resistance Level $5.35 $1.81
Average True Range (ATR) 0.10 0.08
MACD 0.01 -0.01
Stochastic Oscillator 57.02 18.75

Price Performance

Historical Comparison
EARN
IPHA

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: